14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VNDA vs VOR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VOR Captures Overall Composite Edge (57.8 HOLD vs 49.0 HOLD), While VNDA Leads 3–2 on Growth & Valuation Pillars
VOR Overall Winner
6-Pillar Tally: VNDA 3 – 2 VOR (1 Tie)
Matrix Metrics: VNDA 3 – 7 VOR
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (57.8/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Profitability & Quality, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. VNDA trades at $3.79 (103.1x Forward P/E, -77.6% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. VNDA 49.0/100 HOLD) and 1.91β · 61% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VNDA vs VOR. Trailing 12-month operating profitability (VNDA -77.6% vs VOR 0.0%) and valuation multiples (VNDA 103.1x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
VOR Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VNDA vs VOR Key Questions & Quantitative Answers
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Vanda Pharmaceuticals Inc. (VNDA) on higher Unified Composite conviction (57.8/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Profitability & Quality, Options & Positioning), while VNDA wins 3–2 across the 6-pillar growth and valuation breakdown. VNDA trades at $3.79 (103.1x Forward P/E, -77.6% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. VNDA 49.0/100 HOLD) and 1.91β · 61% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VNDA leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VNDA generates $229M in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.
VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus VOR (-125.4% ROE) capital efficiency.
In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.